The two studies showed that the inhibition of YAP by either genic or pharmacological ablation restores the cytotoxicity of BRAF and MEK inhibitors and EGFR-TKIs to NSCLC cells [89,97]. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.